U.S. Health Secretary Robert F. Kennedy Jr. announced plans to reform the National Vaccine Injury Compensation Program (VICP), pledging to address what he calls inefficiencies and corruption within the system. Kennedy, a long-time vaccine skeptic and former vaccine injury lawyer, criticized the program’s “Vaccine Court” for failing to quickly and fairly compensate individuals harmed by vaccines.
In a post on X, Kennedy said he is working with Attorney General Pam Bondi to restore the program to its “original congressional intent,” arguing that its current structure unfairly positions the Department of Health and Human Services (HHS), which he leads, as the defendant rather than vaccine manufacturers.
This move continues Kennedy’s sweeping efforts to reshape U.S. vaccine and health policy. In June, he dismissed all 17 members of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, replacing them with seven appointees, including figures with histories of questioning vaccine safety. One of these members previously earned significant fees as an expert witness against Merck’s Gardasil vaccine, a case in which Kennedy played a key role.
Kennedy is also reportedly considering removing members of another influential health advisory panel, the U.S. Preventive Services Task Force. His tenure at HHS has intensified scrutiny due to his longstanding promotion of vaccine skepticism, including discredited claims linking vaccines to autism and false statements about fetal cells in the measles vaccine.
The announcement comes amid one of the worst U.S. measles outbreaks in decades, further fueling debate over vaccine safety, public health policy, and Kennedy’s leadership approach.


Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee
Trump Set to Begin Final Interviews for Next Federal Reserve Chair
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Federal Judge Orders Restoration of SEVIS Status for Tufts PhD Student Rumeysa Ozturk
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Australia’s Under-16 Social Media Ban Sparks Global Debate and Early Challenges
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute
Democrats Face Uphill Battle in Midterm Elections Despite Recent Victories, Reuters/Ipsos Poll Shows
Trump Administration Unveils High-Priced “Trump Gold Card” Visa Program
U.S. Intelligence Briefly Curtailed Information Sharing With Israel Amid Gaza War Concerns
Trump Administration Fuel-Efficiency Rollback Could Raise Long-Term Costs for U.S. Drivers
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
US Charges Two Men in Alleged Nvidia Chip Smuggling Scheme to China
Trump Claims Thailand-Cambodia Ceasefire After Intense Border Clashes
Trump Signals Conditional Push for Ukraine Peace Talks as Frustration Mounts 



